Physician profile
John E Stanhope
NPI 1740331016
$1,751.50
in general payments reported to CMS, 2019-2025
24 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.43 · 2020: $90.72 · 2021: $403 · 2022: $728 · 2023: $144 · 2024: $104 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $356.36 | 2021-2024 | Linq II |
| Abbott Laboratories | $293.65 | 2022-2023 | Proclaim |
| Novo Nordisk INC | $236.76 | 2021-2025 | Ozempic, Rybelsus |
| Aerin Medical INC. | $135.00 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $109.98 | 2021-2022 | |
| Amarin Pharma, INC. | $107.87 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $97.18 | 2022 | |
| Lilly USA, LLC | $57.44 | 2020-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $41.06 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $41.03 | 2020-2021 | |
| Abbvie INC. | $35.87 | 2021 | |
| Neurelis, INC. | $31.84 | 2022 | |
| Sk Life Science, INC. | $31.84 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $24.53 | 2022 | |
| Ge Healthcare | $21.63 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $18.66 | 2023 | Austedo |
| Exact Sciences Corporation | $17.18 | 2023 | Cologuard Collection Kit |
| Mannkind Corporation | $16.88 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.14 | 2022 | |
| Amgen INC. | $14.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.64 | 2021 | |
| Mdd US Operations, LLC | $14.59 | 2023 | Gocovri |
| Ucb, INC. | $13.11 | 2023 | Nayzilam |
| Grt US Holding, INC. | $3.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stanhope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.